China National Biotec Group (CNBG) is 79.34% effective at protecting people from COVID-19 and the company is seeking regulatory approval for general public use in China, the developer said on Wednesday.The efficacy rate, based on interim analysis of Phase 3 clinical trials, is lower than 86% rate for the same vaccine announced by the United Arab Emirates on Dec.